Business Wire

Finance Monthly Announces Speedcast Chief Executive Officer as Recipient of CEO Award 2017

3.7.2017 20:30 | Business Wire

Del

Speedcast International Limited (ASX: SDA), the world’s most trusted provider of highly reliable, fully managed, remote communication and IT solutions, today announced its Chief Executive Officer Pierre-Jean Beylier has been selected as one of the winners of the Finance Monthly CEO Awards 2017. This accolade recognises Beylier’s outstanding financial achievements at Speedcast over the past 12 months.

Beylier has been with Speedcast since December 2000 and was appointed CEO in July 2004. Under his leadership, Speedcast has become the leader in the global satellite services industry, servicing customers in over 100 countries with operations on land, at sea and in the air. He spearheaded the group’s external growth strategy, acquiring 14 companies over the last five years, successfully building market share, developing a unique product and services portfolio, and leading its successful IPO on the Australian stock exchange in August 2014.

“I am honored to receive the Finance Monthly’s CEO Award for 2017,” said Beylier. “I would like to thank Speedcast’s dedicated employees for their passion and hard work. We would not be able to achieve what we did today without the support and commitment of all our employees and customers.”

Award nominations are open worldwide to all C-level executives from private or public companies. Researchers at Finance Monthly determine the suitability of the CEO/C-Level Executive based on his or her achievements. Achievements are defined and scored upon the following criteria; growth in revenues and/or profits, turnaround transformation, exceeding expectations in difficult markets, growth within new markets, leading market share, successful M&A integration, delivering and producing new products and services. More information about the Finance Monthly CEO Awards can be found at https://ceoawards.finance-monthly.com/.

About Speedcast International Limited

Speedcast International Ltd (ASX: SDA) is the world’s most trusted provider of highly reliable, fully managed, end-to-end remote communication and IT solutions. The company utilizes an extensive worldwide footprint of local support, infrastructure and coverage to design, integrate, secure and optimize networks tailored to customer needs. With differentiated technology, an intense customer focus and a strong safety culture, Speedcast serves more than 2,000 customers in over 140 countries via 39 teleports, including offshore rigs and cruise ships, 10,000+ maritime vessels and 4,500+ terrestrial sites. Speedcast supports mission-critical applications in industries such as maritime, oil and gas, enterprise, media, cruise and government. Learn more at www.Speedcast.com.

Social Media: Twitter | LinkedIn | Facebook

Speedcast® is a trademark and registered trademark of Speedcast International Limited. All other brand names, product names, or trademarks belong to their respective owners.

© 2017 Speedcast International Limited. All rights reserved.

Contact information

Speedcast International Ltd
Toni Lee Rudnicki, +1-832-668-2634
Vice President, Global Marketing
ToniLee.Rudnicki@Speedcast.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42Pressemelding

Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti

SFL – First-Half 2017 Results27.7.2017 17:00Pressemelding

Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)                

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00Pressemelding

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 12:30Pressemelding

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08Pressemelding

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05Pressemelding

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom